In summary, whether in hoof DD or other skin infections, the underlying process involves disruption of skin/hoof microbial homeostasis under external stress, leading to loss of protective microbial function and dominance of pathogenic microorganisms
Patients with established cardiovascular disease (heart attack, stroke history) who benefit from semaglutides proven MACE reduction (SELECT trial) Adolescents aged 1217 with obesity Wegovy is the only approved GLP-1 option in this age group Patients who prefer or need an oral medication option (Rybelsus tablets for type 2 diabetes) Those for whom semaglutide is more affordable or better covered by insurance Patients with metabolic dysfunction-associated steatohepatitis (MASH) Wegovy HD received approval for this indication in 2025 First-time GLP-1 users who want to start with the medication with the longest real-world safety track record Frequently Asked Questions Is tirzepatide stronger than semaglutide
Monitoring and Support Followup visits with Brenda Johnson allow for adjustments in dose or direction based on your progress and any side effects
Others have stopped taking it for different reasons, such as cost, unpleasant side effects or unrelated health issues
Some people take it as a weekly shot, others as a daily tablet, and the dose can change over time
